Standout Papers

The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint 2023 2026 202463
  1. The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint (2023)
    Linus Jönsson, Anders Wimo et al. The Lancet Regional Health - Europe

Immediate Impact

2 from Science/Nature 57 standout
Sub-graph 1 of 23

Citing Papers

Biomarker Changes during 20 Years Preceding Alzheimer’s Disease
2024 Standout
Medical, surgical, and physical treatments for Parkinson's disease
2024 Standout
3 intermediate papers

Works of Ron Handels being referenced

Cognitive behavioural therapy for anxiety disorders in Parkinson's disease: Design of a randomised controlled trial to assess clinical effectiveness and changes in cerebral connectivity
2018
Biomarkers as Predictors for Conversion from Mild Cognitive Impairment to Alzheimer-Type Dementia: Implications for Trial Design
2010

Author Peers

Author Last Decade Papers Cites
Ron Handels 607 263 217 312 60 983
Kristin Kahle‐Wrobleski 618 129 285 251 42 1.2k
Suresh Sahadevan 520 99 188 240 26 1.1k
Heather Davila 353 83 246 180 45 877
Guk‐Hee Suh 524 104 194 178 48 796
Doris Svetlik 516 79 213 335 23 1.1k
Eugene Tang 627 86 184 143 55 1.1k
Edgar Nunes de Moraes 375 98 217 246 74 1.1k
Thien Kieu Thi Phung 616 98 290 128 37 1.1k
Anita Goh 401 58 237 159 50 925
H. Erzigkeit 619 98 174 148 23 952

All Works

Loading papers...

Rankless by CCL
2026